Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Arecor Therapeutics Plc LSE:AREC London Ordinary Share GB00BMWLM973 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 265.00 250.00 280.00 265.00 265.00 265.00 377 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.2 -6.9 -0.3 - 74

Arecor Therapeutics PLC Arecor on Investor Meet Company Platform

02/08/2022 4:52pm

RNS Non-Regulatory


TIDMAREC

Arecor Therapeutics PLC

02 August 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

Arecor to present on Investor Meet Company Platform

Cambridge, UK, 2 August 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Sarah Howell, Chief Executive Officer and Susan Lowther, Chief Financial Officer will be providing a live presentation relating to the Group's recently announced proposed acquisition of Tetris Pharma Ltd. via the Investor Meet Company platform, on Thursday 4 August 2022 at 10:00am BST.

The presentation is open to all existing and potential shareholders and will be followed by a Q&A session. Questions can be submitted ahead of the event through the Investor Meet Company dashboard until 9am BST on Wednesday 3 August, or at any time during the live presentation.

To sign up to Investor Meet Company for free and to register for Arecor's presentation, please visit: https://www.investormeetcompany.com/arecor-therapeutics-plc/register-investor . Investors who already follow Arecor on the Investor Meet Company platform will automatically be invited to the event.

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                    www.arecor.com 
 Dr Sarah Howell, Chief Executive Officer   Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer     Tel: +44 (0) 1223 426060 
                                             Email: info@arecor.com 
 
 Mo Noonan, Communications                  Tel: +44 (0) 7876 444977 
                                             Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD         Tel: +44 (0) 20 7886 2500 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela         Tel: +44 (0) 20 3709 5700 
  Gray                                       Email: arecor@consilium-comms.com 
 

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM) , we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat (TM) platform is supported by an extensive patent portfolio .

For further details please see our website, www.arecor.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAPTMATMTIMBRT

(END) Dow Jones Newswires

August 02, 2022 11:52 ET (15:52 GMT)

1 Year Arecor Therapeutics Chart

1 Year Arecor Therapeutics Chart

1 Month Arecor Therapeutics Chart

1 Month Arecor Therapeutics Chart
ADVFN Advertorial
Your Recent History
LSE
AREC
Arecor The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220929 11:28:54